S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Drought-struck Barcelona quenches thirst with costly desalination
NASDAQ:RAPT

RAPT Therapeutics (RAPT) Earnings Date, Estimates & Call Transcripts

$20.35
+0.30 (+1.50%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$19.98
▼
$20.48
50-Day Range
$16.06
▼
$21.34
52-Week Range
$12.85
▼
$32.45
Volume
168,900 shs
Average Volume
439,286 shs
Market Capitalization
$699.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.22
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 10Estimated
Actual EPS
(Mar. 14)
-$0.64 Beat By $0.03
Consensus EPS
(Mar. 14)
-$0.67
Last Year's Q1 EPS
(3/10/2022)
-$0.61
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RAPT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RAPT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

RAPT Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20234($0.91)($0.51)($0.70)
Q2 20234($1.00)($0.54)($0.75)
Q3 20234($1.01)($0.57)($0.78)
Q4 20234($1.09)($0.54)($0.81)
FY 202316($4.01)($2.16)($3.05)
Q1 20241($0.88)($0.88)($0.88)
Q2 20241($0.91)($0.91)($0.91)
Q3 20241($1.00)($1.00)($1.00)
Q4 20241($1.06)($1.06)($1.06)
FY 20244($3.85)($3.85)($3.85)

RAPT Earnings Date and Information

RAPT Therapeutics last issued its quarterly earnings data on March 14th, 2023. The reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.03. RAPT Therapeutics has generated ($2.65) earnings per share over the last year (($2.65) diluted earnings per share). Earnings for RAPT Therapeutics are expected to decrease in the coming year, from ($3.18) to ($3.42) per share. RAPT Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off prior year's report dates.

RAPT Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/10/2023
(Estimated)		        
3/14/2023Q4 2022($0.67)($0.64)+$0.03($0.64)
11/10/2022Q3 2022($0.65)($0.63)+$0.02($0.63)
8/11/2022Q2 2022($0.75)($0.62)+$0.13($0.62)$0.40 million$0.89 million
5/11/2022Q1 2022($0.66)($0.69)($0.03)($0.69)$0.40 million$0.64 million
3/10/2022Q4 2021($0.66)($0.61)+$0.05($0.61)$1.50 million$0.76 million
11/10/20219/30/2021($0.62)($0.63)($0.01)($0.63)$1.45 million$0.97 million
8/11/20216/30/2021($0.68)($0.63)+$0.05($0.63)$1.43 million$0.87 million
5/11/20213/31/2021($0.60)($0.66)($0.06)($0.66)$1.70 million$1.22 million
3/11/202112/31/2020($0.58)($0.52)+$0.06($0.52)$2.05 million$1.30 million
11/15/20209/30/2020($0.56)($0.60)($0.04)($0.60)$2.50 million$1.53 million
8/13/2020Q2 2020($0.5770)($0.5090)+$0.0680($0.51)$2.50 million$1.28 million
5/14/20203/31/2020($0.43)($0.56)($0.13)($0.56)$2.50 million$0.94 million
3/30/202012/31/2019($0.74)($0.82)($0.08)($0.87)
12/11/2019Q3 2019($6.15)($12.41)($6.26)($12.41)












RAPT Therapeutics Earnings - Frequently Asked Questions

When is RAPT Therapeutics's earnings date?

RAPT Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off last year's report dates. Learn more on RAPT's earnings history.

Did RAPT Therapeutics beat their earnings estimates last quarter?

In the previous quarter, RAPT Therapeutics (NASDAQ:RAPT) reported ($0.64) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.67) by $0.03. Learn more on analysts' earnings estimate vs. RAPT's actual earnings.

How much revenue does RAPT Therapeutics generate each year?

RAPT Therapeutics (NASDAQ:RAPT) has a recorded annual revenue of $1.53 million.

How much profit does RAPT Therapeutics generate each year?

RAPT Therapeutics (NASDAQ:RAPT) has a recorded net income of -$83.84 million. RAPT has generated -$2.65 earnings per share over the last four quarters.

What is RAPT Therapeutics's EPS forecast for next year?

RAPT Therapeutics's earnings are expected to decrease from ($3.18) per share to ($3.42) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:RAPT) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -